PTC Therapeutics Q3 2026 Earnings: Sephience Drives Revenue as ST-920 Costs Weigh on Profit

PTC Therapeutics (NASDAQ: PTCT) reported Q3 2026 revenue of $357.8 million, up approximately 69.6% from $211.0 million a year earlier, while diluted EPS moved to a loss of $0.62 from earnings of $0.20. Product revenue more than doubled to $275.9 million as Sephience generated $181.9 million, but a $111.0 million acquired in-process R&D charge for ST-920 and higher financing-related costs left the company with a $51.7 million net loss. PTC also raised its full-year product revenue guidance.

Core Financial Results

Revenue growth was primarily driven by the commercial portfolio. Net product revenue increased approximately 110.7%, while royalty revenue rose to $81.7 million from $70.8 million; collaboration and license revenue declined to $0.2 million from $9.3 million.

Operating income improved to $25.1 million despite the ST-920 acquisition charge, but interest expense, a debt-extinguishment loss, and income tax expense pushed the bottom line into a loss.

Business and Product Performance

Sephience was the main commercial growth engine, producing $181.9 million of revenue and growing 20% from Q2 2026. The total included $145 million from the US and $37 million from markets outside the US, with more than 2,000 active patients worldwide as of September 30.

Legacy products moved in the opposite direction. Translarna revenue declined modestly and included a Russian government purchase order, while Emflaza revenue fell approximately 28.7%. Evrysdi royalties continued to increase.

Sephience represented approximately 66% of quarterly product revenue and 51% of total revenue, making its launch trajectory increasingly important to PTC’s overall results.

Sephience Growth Lifted Operations, but Acquisition and Financing Costs Drove the Net Loss

Total operating expenses increased by approximately $124.7 million to $332.7 million. The $111.0 million acquired in-process R&D expense associated with ST-920 accounted for most of that increase. Even after absorbing the charge, higher revenue allowed operating income to rise to $25.1 million from $3.0 million.

The larger pressure appeared below operating income. Net interest expense increased to $45.9 million from $32.6 million, and PTC recorded a $19.3 million loss on debt extinguishment. A $10.6 million income tax expense also contrasted with a $39.0 million tax benefit in Q3 2025, when the company reported net income despite a pre-tax loss.

Underlying operating expenses were more stable. GAAP R&D expense increased approximately 5.2% to $105.4 million, while non-GAAP R&D expense rose to $94.9 million from $91.0 million. GAAP SG&A expense declined approximately 4.7% to $80.1 million, and non-GAAP SG&A fell to $66.7 million from $73.8 million. The non-GAAP figures exclude stock-based compensation.

Balance Sheet and Capital Commitments

Cash, cash equivalents, and marketable securities totaled $2.128 billion at September 30, 2026, up from $1.945 billion at the end of 2025. Over the same period, total debt increased to $536.3 million from $286.6 million, while the liability related to the sale of future royalties remained substantial at $2.306 billion.

PTC paid $111.0 million upfront to acquire ST-920. The agreement also includes up to $100.0 million of additional payments tied to US regulatory approvals, creating a potential future cash commitment if the program reaches those milestones.

Pipeline and Regulatory Milestones

PTC expects to complete the ST-920 Biologics License Application submission in Q4 2026. The company views accelerated FDA approval and a 2027 commercial launch as potential outcomes, although both remain dependent on regulatory review.

For votoplam in Huntington’s disease, an FDA Type C meeting to discuss Phase 2 data and a potential accelerated approval pathway is now scheduled for Q1 2027 because of FDA scheduling. The global Phase 3 INVEST-HD study is enrolling toward a target of approximately 770 early symptomatic patients.

PTC also initiated the approximately 120-patient PROVE-FA study of vatiquinone during Q3 to support an NDA resubmission in Friedreich’s ataxia. Other pipeline activity included the start of a Phase 2a study of PTC844, continued advancement of the Phase 1 PTC612 study, and plans to move PTC303 into clinical development in 2027.

Full-Year 2026 Guidance

PTC raised full-year product revenue guidance to $960 million-$990 million from $850 million-$950 million. The midpoint increased by $75 million to $975 million, while the range narrowed. The company also increased its total revenue outlook, although the previous total revenue range was not included in the release.

Management said continued Sephience momentum keeps PTC on track to reach its cash flow breakeven milestone in 2026.

Recent Insider Transactions

The supplied six-month insider summary shows 206,017 shares acquired across 17 transactions and 287,526 shares sold across 21 transactions, resulting in net sales of 81,509 shares. That represented 1.30% of total insider holdings. The most recently reported individual transactions consisted of derivative-security conversions and sales; the values below are the reported transaction amounts.

These disclosures describe the transactions but do not establish the insiders’ reasons for completing them.

Risks Investors Need to Watch

• Dependence on Sephience: Sephience generated approximately two-thirds of product revenue. Changes in adoption, pricing, coverage, or reimbursement could have an outsized effect on product revenue and updated guidance.
• Declining legacy product sales: Translarna and Emflaza revenue declined year over year. Translarna also faces regulatory uncertainty, and its quarterly results can be influenced by government purchase orders.
• Regulatory and development execution: The ST-920 submission, votoplam regulatory discussions, and vatiquinone study remain subject to regulatory timelines and clinical outcomes. The votoplam Type C meeting has already moved to Q1 2027 because of FDA scheduling.
• Financing costs and obligations: Higher debt, $45.9 million of quarterly net interest expense, and a $2.306 billion future-royalty liability can limit how much commercial growth reaches net income and cash generation.
• Acquisition-related commitments: ST-920 resulted in a $111.0 million upfront charge and could require another $100.0 million if specified US regulatory milestones are achieved.

Summary

PTC Therapeutics’ third-quarter revenue growth was led by the Sephience launch and higher Evrysdi royalties, more than offsetting declines in Translarna and Emflaza. The commercial progress improved operating income and supported higher full-year revenue guidance, but the ST-920 acquisition charge, interest expense, debt-extinguishment loss, and tax expense produced a GAAP net loss. The next major points to monitor are Sephience’s international expansion, delivery against the revised guidance, the ST-920 BLA submission, and whether stronger operating performance translates into management’s targeted cash flow breakeven.